SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
President Donald Trump signs S.1852, The GENIUS Act, Friday, July 18, 2025, in the East Room of the White House. (Official White House Photo by Daniel Torok)
Drug pricing
Trump Asks Big Pharmas To Move on Most Favored Nation Drug Pricing—Or Else
In 17 identical letters posted to his Truth Social account, the president said companies must lower their prices or the government ‘will deploy every tool in our arsenal to protect American families from continued drug pricing practices.’
July 31, 2025
 · 
2 min read
 · 
Dan Samorodnitsky
Facade of the FDA's office in Maryland
Regulatory
FDA Issued Myeloma, Alzheimer’s Approvals in July but Rejected Two CGTs
The FDA greenlit multiple new drugs this month and issued some notable label expansions, including for Eli Lilly’s Kisunla. Meanwhile, the regulator turned away a cell therapy for Duchenne muscular dystrophy and a gene therapy for the rare disease Sanfilippo syndrome.
July 31, 2025
 · 
10 min read
 · 
Tristan Manalac
Problems and Challenges. Businessman stands on question mark
Earnings
Future of BMS’ Cobenfy Still in Limbo After Phase III Fail
Bristol Myers Squibb tested Cobenfy as an adjunctive treatment with atypical antipsychotics for schizophrenia in the Phase III ARISE study, which earlier this year failed to demonstrate significant symptom improvement.
July 31, 2025
 · 
2 min read
 · 
Tristan Manalac
Protection From Tariffs as an An umbrella that shields against import and export tariff taxes as a trade war storm increasing prices and straining supply chains as a business metaphor and a symbol for resilience in times of crisis and economic downturn.
Earnings
Sanofi Confident Tariffs Will Have Limited Impact on Finances in 2025
For now, Sanofi’s U.S. inventory is insulating the company from a potential 15% tariff on drugs shipped from the EU.
July 31, 2025
 · 
2 min read
 · 
Nick Paul Taylor
AbbVie's office in South San Francisco, California
Earnings
AbbVie Pats Own Back as Skyrizi and Rinvoq Rake in Billions
Move over Humira, Skyrizi and Rinvoq are expected to beat the former megablockbuster’s peak sales by the end of this year.
July 31, 2025
 · 
2 min read
 · 
Dan Samorodnitsky
Businessman pushing boulder uphill vector concept of Sisyphus. Symbol of hard work, futile effort, strength, struggle, challenge but also motivation and ambition. Eps10 vector illustration.
Earnings
Biogen’s Leqembi Push Getting Easier as CEO Eyes Early-Stage Pipeline Restock
Rumors of Biogen’s disagreements with Eisai have been greatly exaggerated, CEO Chris Viehbacher said during a second quarter earnings call. The partnered Alzheimer’s drug Leqembi saw sales climb 20% for the period.
July 31, 2025
 · 
4 min read
 · 
Annalee Armstrong
Pictured: Facade of Moderna's building in Massachusetts
Layoffs
Moderna Slashes Global Workforce by 10% as $1.5B Cost Cuts Hit Home
The announced reduction of hundreds of staff came a day ahead of Moderna’s Q2 earnings report.
July 31, 2025
 · 
1 min read
 · 
Annalee Armstrong
Pictured: Eli Lilly's headquarters in Indianapolis
Diabetes
Lilly’s Mounjaro ‘Good Enough’ in Cardio Trial, Will Seek Expanded Approval
While Eli Lilly’s diabetes blockbuster was non-inferior to its older incretin therapy Trulicity in a highly anticipated Phase III cardiovascular outcomes trial, analysts had hoped for statistical significance in reducing major events such as cardiovascular death, heart attack and stroke.
July 31, 2025
 · 
2 min read
 · 
Heather McKenzie
Illustration of escape key in human hands
Job Trends
Greener Pastures? 81% of Employed Biopharma Professionals Want New Jobs, BioSpace Finds
Employed biopharma professionals are highly likely to look for new jobs in the next 12 months, although not quite as likely as their unemployed counterparts, according to a BioSpace LinkedIn poll. Three recruitment experts discuss the findings and what’s driving job searches.
July 31, 2025
 · 
4 min read
 · 
Angela Gabriel
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS